Highlights {#Sec1}
==========

Needle-free connectors are safe in a surgical setting.

Background {#Sec2}
==========

Catheter-related bloodstream infections (CRBSI) are preventable, but common healthcare-associated infections. Apart from increasing the length of intensive care unit (ICU) treatment, they are associated with the risk to cause life-threating infections. Common ports of entry for the infectious agents are indwelling intravascular catheters, such as arterial lines and central venous catheters (CVC). The treatment with peripherally incompatible infusions (e.g., hyperosmolar drugs, sedatives, parental nutrition) requires a CVC placement. CVC-related infections occur on 1.02 days per 1000 CVC-days \[[@CR1]\] and 60% of intensive care unit (ICU) patients require a CVC. New strategies to reduce contamination via an indwelling central venous or arterial catheter could, therefore, improve patient outcome.

Before the actual bloodstream infections occur, intravascular catheter entry ports often become contaminated with bacteria. Such contaminations occur during handling of intravascular line connectors during the connection of infusions, injections of drugs or blood sample withdrawal. Especially multivolume catheters, therefore, bear a higher risk of infection, due to the higher frequency of connections and disconnections of infusions \[[@CR2]\]. Multiple studies have evaluated measurements to reduce CVC contaminations using sterile dressings, anti-infective coatings, antibiotic-impregnated catheters and multi-step bundles consisting of washing procedures with antiseptic solutions. In Germany, the commission of the federal government for hospital hygiene and infection prevention (*Kommission für Krankenhaushygiene und Infektionsprävention, Robert-Koch-Institut; RKI*) recommends the use of needle-free connectors (NFC) to reduce the risk of infection. This recommendation relies on the rationale, that NFC may reduce manipulation on the CVC connections and therefore reduce the time microorganism can contaminate the ports \[[@CR3]\]. If NFC decrease CRBSI remains a matter of debate, since some trials found no impact on infections, whereas case-series found an increase in systemic infections \[[@CR4], [@CR5]\].

To test, if NFC usage could influence CRBSI rates in surgical patients, we performed a prospective randomized trial using a novel needleless connector (Bionecteur®, Vygon Inc.) in surgical ICU setting, and analyzed repetitive microbiological samplings of the connectors on arterial lines and central venous catheters as a surrogate for bacterial contamination and blood cultures.

Methods {#Sec3}
=======

Ethics {#Sec4}
------

This prospective clinical trial was approved by the Ethics Committee of the University Hospital Tuebingen prior to recruitment (394/2014MPG23). Before randomization, written consent was acquired from all patients or their legal representative prior to study inclusion. If the patient was incapable to provide informed consent but no advanced directive regarding the legal representative was made, a formal legal guardianship was requested at the respective dependency court. If a legally binding informed consent was absent prior to the first study intervention, the patients were excluded from the study. The study was registered in Clinical Trial Database (NCT02134769).

Study setting, population and sample size {#Sec5}
-----------------------------------------

The study was performed as a simple, single-center randomized controlled trial at tertiary, university hospital intensive care unit. The study included patients requiring a central venous catheter or an arterial cannula for monitoring or therapy.

Inclusion and exclusion criteria {#Sec6}
--------------------------------

Inclusion criteria were 18 years of age or older, admission to the intensive care unit, the necessity for a central venous catheter or arterial line, anticipated ICU treatment for more than 5 days and informed consent by the legal representative. Exclusion criteria included ICU stay for less than 3 days (including non-survival), positive blood cultures prior to first infusion line change, the unknown time point of catheter placement, catheter placement at a referring hospital or absence of informed consent. Patients with intellectual disability were also excluded from the study.

Primary and secondary endpoint {#Sec7}
------------------------------

The primary endpoint of our study was the number of CRBSI. Secondary endpoints were bacterial colonization of intravascular catheter line entry ports.

Definition of catheter-related bloodstream infections and clinical criteria {#Sec8}
---------------------------------------------------------------------------

In line with international guidelines \[[@CR6], [@CR7]\], CRBSI was diagnosed when the following criteria were met: bacteremia/fungemia in a patient with an intravascular catheter with at least one positive blood culture obtained from a peripheral vein, catheter tip colonization, no apparent source for the bloodstream infection except the catheter and clinical manifestations of infection. Clinical criteria for an infection were fever (body temperature \> 38 °C), tachycardia, tachypnea, hypotension or increase of vasopressors by more than 50% in 24 h, chills in the presence of elevated inflammatory markers (C-reactive protein \> 5 mg/dl postoperatively, procalcitonin \> 0.5 ng/ml).

Study protocol and randomization {#Sec9}
--------------------------------

Intravascular catheters were either placed in the operating room just prior to ICU admission or after ICU admission under sterile conditions. Patients received intravascular catheter solely for the management of the underlying disease. On day 3 after ICU admission, the attending intensivist on call screened patients for inclusion or exclusion criteria and enrolled the patients if applicable. If patients were included in the study, patients were randomized into either the NFC group or the control group. Numbered, concealed envelopes were used for randomization based on a randomization list generated by the Institute of Biometrics at the University of Tuebingen. In the treatment group, we replaced caps by NFCs (Fig. [1](#Fig1){ref-type="fig"}). All staff involved in patient care received training in the use of NFCs used in our study (Vygon Bionecteur®) prior to the study. Fig. 1Flow chart of screening and randomization

The study protocol entailed a programmed change of the central venous pressure infusion lines and arterial pressure infusion line every 72 h. We collected a set of blood cultures prior to the change of infusion lines for the first time. Simultaneously to infusion line changes, microbiological samples were collected from each port of the CVC or arterial lines. Before each handling of the ports, spray disinfection before application of medication or before changing infusion lines was performed. All infusion hubs of a four-way stopcock were capped by a sterile cap.

Microbiological analysis was performed by the Institute of Medical Microbiology at the University Tuebingen according to routine standard-operating procedures. The medical microbiologist was blinded to the study group.

Staff training {#Sec10}
--------------

Before the study, all nursing staff and physicians of our intensive care unit were trained in the handling of NFCs. In a first step, the manufacturer of Bionecteur, Vygon Inc®, trained senior critical care nurses, who also hold a certificate as practical nursing trainers. Then, the nursing care trainers served as proxies and subsequently trained all other staff within a 4 weeks' time frame. The study protocol was initiated after all personnel had completed training in NFC handling.

Access-ports nursing care {#Sec11}
-------------------------

Before handling, NFCs were sprayed with a 70% propranolol-based antiseptic solution and then scrubbed for 15 s. After an additional wait period of 15 s to allow the antiseptic solution to dry, the NFC entry ports were then handled.

In the control group, the three-way stopcocks were also sprayed with a 70% propranolol-based antiseptic solution after uncapping and before infusion lines were connected or medication injected. A new, sterilely packed end-cap was placed on the three-way stopcock after each handling.

Regardless of the study group, both systems were flushed with a bolus of several milliliters of normal saline after injection of medication.

Statistical analysis {#Sec12}
--------------------

Statistical planning and evaluation were performed by the Institute of Biometrics at the University of Tuebingen. The data were analyzed by Mann-Whitney and *T* test. A *p* value of \< 0.05 was considered significant.

Results {#Sec13}
=======

Patients {#Sec14}
--------

During the planning phase, a sample size of 300 patients (150 per group) was calculated, based on the incidence of CRSBI in surgical ICUs. Between April 2014 and October 2016, 2700 patients were screened. A total of 2480 patients met the exclusion criteria. Trial recruitment ended at the pre-defined deadline in October 2016. Two hundred twenty patients were randomized. Exclusion criteria were fulfilled in 87 patients in the NFC group and 86 patients in the control group (Fig. [1](#Fig1){ref-type="fig"}). The main reason for exclusion was the absence of a legal representative. Ultimately, we analyzed data from 24 patients in the NFC group and 23 patients.

The patient population did not differ in basic demographics (e.g., age or gender) or regarding co-morbidities (Table [1](#Tab1){ref-type="table"}). Most of the patients were admitted for postoperative surveillance and critical care management after cardiac surgery. Pneumonia was common in both groups on admission. Taken together, the NFC and the control group showed comparable baseline characteristics. Table 1DemographicsNFC\
(*n* = 24)Controls\
(*n* = 23)*p* valuesAge---year (mean ± SD)64.2 ± 16.865.5 ± 11.30.76Male sex---no. (%)15 (58)13 (57)0.76Co-morbidities Coronary artery disease7 (30.4)5 (20.8)0.06 Arterial hypertension15 (65.2)19 (79.2)0.19 Chronic obstructive pulmonary disease1 (4.3)2 (8.3)0.61 Diabetes mellitus type II6 (26.1)8 (33.3)0.53Admitting surgical specialty Cardiothoracic surgery (%)11 (41)16 (59)0.14 General surgery (%)6 (25)5 (22)\> 0.99 Other6 (25)2 (9)0.24ICU admission diagnosis Postoperative surveillance after cardiac surgery (%)10 (43.5)9 (37.7)\> 0.99 Abdominal surgery (laparotomy)4 (17.4)1 (4.2)0.35 Intracranial hemorrhage03 (12.5)0.11 Acute respiratory distress syndrome2 (8.7)2 (8.3)0.99 Sepsis01 (4.2)0.49 Pneumonia18 (78.3)14 (58.3)0.36 SIRS3 (13)2 (8.3)\> 0.99 Peritonitis3 (13)1 (4.2)0.61 Urinary tract infection3 (13)4 (16.6)0.70 Others7 (30.4)8 (33.3)0.76

Change of infusion lines, arterial or central venous catheters {#Sec15}
--------------------------------------------------------------

After having defined the general characteristics, we analyzed the variables increasing the risk for CRBSI. Even though patients in the control group stayed longer in the ICU (median 23 days) than patients in the NFC group (19 days), the difference was not significant. In 34.8% of the control patients and in 29.1% of the NFC group more than one new placement of a CVC line was necessary. On average, CVC remained in situ for an average of 10.6 ± 5.8 days in the NFC or 10.4 ± 4.2 days in the control population (*p* = 0.89) (Table [2](#Tab2){ref-type="table"}). Table 2ICU variables and microbiological sampling parametersNFC\
(*n* = 24)Controls\
(*n* = 23)*p* valuesMedian days length of ICU stay (interquartile range)19 (11.5--29.0)23 (15.0--31.00)0.41Median number of infusion line changes (interquartile range)5 (3--8.5)7 (4--8)0.47Median number of CVC changes (interquartile range)2 (1--2.75)2 (2--3)0.06Median days of CVC in situ (interquartile range)9.5 (6--15)10 (8--14)0.89Median number of arterial line changes (interquartile range)1 (0--2)1 (0--2)0.73Central venous catheter location Jugular vein41480.81 Subclavian vein7120.45 Femoral vein200.20Microbiological sampling Median number of entry port sampling (interquartile range)5 (2--7)4 (3--6)0.61 Number of blood cultures collected (%)17 (71)18 (78)0.74 Blood cultures tested positive (% of all)2 (12)4 (22)0.65

Our study protocol did not specify the preferred location for the CVC placement., but CVC location influences the rate of infection \[[@CR8]\]. Thus, we analyzed if the control or the NFC population differed in the site of central venous catheter placement. Most commonly, CVC was most commonly placed in the jugular vein (Table [2](#Tab2){ref-type="table"}). Only on two occasions, the femoral vein was used for CVC placement in the NFC. No difference was detected between the groups. Thus, NFC usage did not influence the number of CVC placements or catheter locations.

Microbiological sampling results {#Sec16}
--------------------------------

In our observational study, we next analyzed, if NFC changed the level of entry port contamination. For this, each entry port was sampled when infusion lines were changes. As shown in Table [3](#Tab3){ref-type="table"}, coagulase-negative staphylococcus dominated the contamination of entry port of arterial lines. The distribution of microbiological genus was identical when the CVC contamination flora was analyzed: here, also the coagulase-negative staphylococci dominated the contamination of the entry ports (Table [4](#Tab4){ref-type="table"}). Next, we analyzed the percentage of bacterial growth in microbiological samples taken from the entry ports of CVC. As shown in Fig. [2](#Fig2){ref-type="fig"}, 75% of CVC entry ports in the NFC group and 78.5% of the entry port in the control group were contaminated during the first programmed change of infusion lines. The infusion lines were renewed every 72 h and we acquired microbiological samples of each entry port on that occasion. Interestingly, the percentage of contaminated ports decreased over time, and no growth could be detected after 6 changes of infusion lines in the NFC group (Fig. [3](#Fig3){ref-type="fig"}). Table 3Microbiological results arterial catheterNFC\
(*n* = 96)Controls\
(*n* = 92)*p* valuesNo growth1301130.16Coagulase-negative staphylococci19160.85 Staphylococcus hominis72 Staphylococcus simulans00 Staphylococcus capitis02 Staphylococcus epidermidis1011 Staphylococcus haemolyticus21Streptococcus mitis--1Micrococcus luteus1-- Table 4Microbiological results in central venous catheterNFC\
(*n* = 168)Controls\
(*n* = 161)*p* valuesNo growth1301130.17Coagulase-negative staphylococci29340.15 Staphylococcus hominis48 Staphylococcus simulans10 Staphylococcus capitis22 Staphylococcus epidermidis1418 Staphylococcus haemolyticus86Corynebacterium tuberculostearicum10 Enterococcus faecium20 Streptococcus mitis12 Streptococcus parasanguinis11 Streptococcus viridans spp01 Pantoea agglomerans10 Enterococcus faecalis11 Micrococcus luteus12 Fig. 2Setup of entry port connectors. **a** Arterial connection before the implementation of NFC; **b** CVC connection before the implementation of NFC including stopcocks and caps; **c** Arterial connection including Bionecteur; **d** CVC connection using Bionecteur including stopcocks and no caps. Arrow marks CVC line Fig. 3Bacterial contamination of entry ports. Percent of the bacterial growth of entry port sampling during sampling period

According to our study protocol, every time an entry port sampling tested positive, a blood culture from a peripheral vein was collected. If a CRBSI was suspected based on clinical signs of infection, blood cultures were collected from a peripheral vein, the catheter was removed, and the catheter line tip underwent microbiological testing. In total, 47 central venous catheter line tips were cultured. We found identical pathogens in blood culture and CVC lines tips in two patients of the NFC group and one patient in the control group, making the diagnosis of CRBSI. Based on these numbers, the calculated device-associated infection rate was 1.83 and 3.8 per 1000 patient days in the control and NFC group, respectively.

Taken together, NFC use had no impact on bacterial contamination of entry port, but data indicate that the use of NFC decreases the rate of contamination over time faster when compared to controls.

Discussion {#Sec17}
==========

In this randomized prospective observational trial, we found that NFC has no impact on bacterial contamination of intravascular catheter entry port or CRBSI rate.

Patients in surgical ICUs require CVCs for drug administration and hemodynamic monitoring, which put them at risk for CRBSI. The reported incidence rate of CRBSI by German National Reference Center for the Surveillance of Nosocomial Infections is 1.02 per 1000 catheter days in surgical ICUs \[[@CR9]\]; reports from our ICU list an even lower incidence of (0.38/1000 catheter days; unpublished internal reports of our institution). However, these numbers warrant caution, since they often rely on the analysis of billing codes. By nature, data from reporting systems relying on billing codes can differ from data gathered in clinical trials. If CRSBI is underdiagnosed and undercoded, it will be underreported. It is therefore not surprising that in our clinical study, we found a much higher incidence rate of CRBSI (2.86/1000 catheter days) than expected.

A risk factor for CVC-associated CRBSI is contamination of entry ports; thus,s interventions reducing contaminations could subsequently reduce rates of CRBSI. Holroyd showed that none of the routine procedures is efficient in decontamination of the inner conus of a stopcock, whereas the surface of the NFC could be decontaminated efficiently \[[@CR10]\]. Furthermore, some of the agents used for disinfection like chlorhexidine \[[@CR11], [@CR12]\]) may include the risk for antibiotic resistance \[[@CR11]\], NFC may represent a device with a lower risk for further resistance. In our study, disinfection was performed according to a recommendation by the manufacturer, nevertheless, we could find contamination at the rim of the CVC connector in 75% out of NFC swabs. Only in one patient of the NFC patients, pathogen present in the connector also leads to a blood-culture positive infection as compared to two CRBSI in the control group. This is in line with previous studies, where NCF also had no impact on the rate of bloodstream infections \[[@CR13]\]. Since the healthcare-associated infections increase with the number of manipulations \[[@CR14]\], this could explain our findings, since our study protocol reduced the number of programmed infusion line changes. This alone could have contributed to the relatively low numbers of CIRBS in our study.

NFC use in our study also did not increase the rate of contamination or CRBSI. This is in contrast to other findings results from retrospective case series \[[@CR15]--[@CR17]\], which found a spike in CRBSI after the introduction of NFCs and the United States Food and Drug Administration recommended to avoid NFCs. In part, this can be explained by the physical construction of the connector we used (Bionecteur®), which differs from previous models since it only allowed a retrograde flow of blood into connectors. This limits the chance of accidental injection of contaminated material present in the connector into the bloodstream. In vitro studies indicate that design only minimally impacts bacterial contamination, whereas the frequent use and usage time primarily determine if bacterial form colony within the connector of the NFCs \[[@CR18]\]. In our study, we changed the NFC every 3 days together with the central and arterial lines, even though the manufacturer recommends the use for 7 days or 360 connections. This could also contribute to the low numbers of contaminations in the NFC group since in vitro studies suggest that bacterial load increases after 4 days regardless of the numbers of disinfections \[[@CR18]\]. The use of stopcocks also bears the risk of bacterial contamination in the dead space \[[@CR19]\], but rates were similarly low in the control group than in the NFC group.

In total, data from only 47 patients underwent analysis and thus the study cohort is not suitable to draw conclusions on the impact of rare events such as catheter-related bloodstream infections. This could be interpreted as a weak point of our trial. Yet, PubMed lists only two clinical trials investigating NFCs in the setting of adult critical care. Both trials were performed more than a decade ago \[[@CR20], [@CR21]\], when the physical construction of NFCs differed from the current models. Nevertheless, various authorities recommend the usage of NFCs to reduce intravascular catheter-associated infections despite uncertain benefits (e.g., German Commission on Hospital Hygiene, KRINKO in 2017). Thus, we feel that our trial provides information in a field with only scarce data to date---albeit based on a small study cohort.

Conclusion {#Sec18}
==========

Taken together, NFC usage for intravascular infusion line port has no impact on bacterial contamination or CRSBI. However, there was a trend towards after sterile conditions in the NFC group, which warrant further investigation.

CVC

:   Central venous catheter

    CRBSI

    Catheter-related bloodstream infection

    ICU

    Intensive care unit

    KRINKO

    Kommission für Krankenhaushygiene und Infektionsprävention

    NFC

    Needle-free connector

    RKI

    Robert Koch Institute
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